5 completed, 1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Idiopathic Myelofibrosis: new trials by email Literature Review of Idiopathic Myelofibrosis trials Research Report on Idiopathic Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis panobinostat, ruxolitinib - Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis | Phase 1 | Completed | Novartis Pharmaceuticals | 61 | 2011-11-01 | 2021-06-25 |
| Familial Myeloproliferative Disorders Polycythemia Vera, Essential Thrombocythemia | Completed | Icahn School of Medicine at Mount Sinai | 17 | 2008-03-01 | 2017-09-05 | |
| Research Tissue Bank Myelofibrosis, Idiopathic Myelofibrosis | Completed | Icahn School of Medicine at Mount Sinai | 963 | 2007-09-01 | 2019-07-05 | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders Myeloproliferative Disease, Myelofibrosis | Completed | Icahn School of Medicine at Mount Sinai | 592 | 2007-04-01 | 2018-12-13 | |
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders Polycythemia Vera, Essential Thrombocytosis | Completed | National Institutes of Health Clinical Center (CC) | 8 | 2007-02-06 | 2017-07-02 |
Primary Myelofibrosis (7) · Polycythemia Vera (5) · Thrombocythemia, Essential (5) · Myeloproliferative Disorders (4) · Blast Crisis (1) · Bone Marrow Neoplasms (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Bone Marrow Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Blood Coagulation Disorders (5) · Blood Platelet Disorders (5) · Hemorrhagic Disorders (5) · Neoplasms (5) · Neoplasms by Site (5) · Thrombocytosis (5) · Bone Marrow Neoplasms (4) · Hematologic Neoplasms (4) · Myeloproliferative Disorders (3) · Chronic Disease (2) · Disease Attributes (2) · Leukemia (2)
Panobinostat (1) · ruxolitinib (1)
Icahn School of Medicine at Mount Sinai (3) · Asana BioSciences (1) · MPN Research Foundation (1) · National Institutes of Health Clinical Center (CC) (1) · Novartis Pharmaceuticals (1)
United States (6) · Italy (4) · United Kingdom (2) · Argentina (1) · Canada (1) · France (1) · Germany (1) · Ireland (1)
Rona S Weinberg, PhD (2) · John Mascarenhas, MD (1) · Josef Prachal, MD (1) · Lewis Silverman, MD (1) · Niranjan Rao, PhD (1) · Raajit Rampal, MD, PhD (1)
P01CA108671 (3)